Comorbidities, hematologic cancers drive high costs among elderly patients

High-cost hospital stays among elderly patients with cancer are associated with major procedures, more comorbid conditions, hematologic cancer, and metastatic cancer, according to a retrospective analysis of more than 570,000 inpatient visits.

Patients involved in the top 10% most expensive cancer-related hospital visits were more likely to have five or more comorbidities, or receive chemotherapy, reported lead author Jaqueline Avila, PhD candidate at the University of Texas Medical Branch in Galveston, and her colleagues.

“A small fraction (approximately 10%) of patients account for more than half of the overall health care costs incurred annually,” the investigators wrote. The report is in the Journal of Oncology Practice.

“[S]imilar to the general population, a small population of patients with cancer (the top 5% to 10% of patients with highest costs) accounts for more than 80% of the total cancer costs,” the investigators wrote. “However, we lack a detailed understanding of the characteristics of these high-cost and high-risk elderly patients with cancer.”

To gain insight, the investigators analyzed 574,367 cancer-related inpatient visits of patients aged 65 years or older, using data from the 2014 National Inpatient Sample. Visits were divided based on cost, with the top 10% most expensive visits in one group (n = 57,437) and the lower 90% of visits in another group (n = 516,930). The investigators then compared these groups based on a variety of patient factor covariates, including race, sex, age, type of cancer, comorbidities, treatments received, and hospital characteristics, such as private or public ownership and location.

The overall median cost of the top 10% of inpatient visits was $38,194 (interquartile range, $31,405-$51,802), compared with $8,257 in the lower-cost group (interquartile range, $5,032-$13,335). This was partly attributed to comorbidities. In the high-cost group, 38.4% of patients had five or more comorbidities, compared with 26.2% in the lower-cost group (P less than .001).

Procedures also factored into cost. The high-cost group had more procedures than did the lower-cost group (mean, 5.48 vs. 2.36; P less than .001), and expensive stays more often entailed major procedures (67.1% vs. 24.3%; P less than .001). Hematologic cancer and metastatic cancer were also more common in the high-cost group than in the lower-cost group, with rates of 23.5% versus 14.6% and 16.5% versus 11.8%, respectively. Among all cancer types, lymphoma, leukemia, and myeloma were the most expensive. The investigators noted that 97.9% of stem-cell or bone marrow transplants were received by patients with hematologic cancer.

Cost did not increase directly with age, as patients aged 65-84 years were more likely to have high-cost inpatient visits than were those who were aged 85 years or older.

The investigators suggested that complications of chronic diseases were likely at the root of this difference, particularly among patients in the 65- to 72-year range. “The difference in costs could also be because caregivers and clinicians may choose to provide only necessary and often less intensive procedures and care to the oldest patients,” the investigators wrote.

A variety of other factors were associated with high-cost visits, although to a lesser degree, including male sex, treatment at a metropolitan teaching hospital, higher median household income, radiation therapy, and large bed size.

The investigators stated that more research is needed to determine relationships between costs and medical necessity, and to develop strategies for reducing costs.

“Although we evaluated the drivers of hospital costs, we could not assess whether additional costs incurred by the high-cost group were medically necessary or could be prevented or whether these excess costs resulted in better outcomes,” the investigators wrote. “Additional research is needed to measure outcomes such as survival and quality of life in this high-cost group and also evaluate whether the excess cost is spent on medically necessary services.

“Future studies should address how implementation of models such as the integrative care model and hospice care may affect the distribution of high-cost and low-cost visits,” the investigators suggested.

Novartis funded the study. Dr. Chavez-MacGregor reported financial relationships with Pfizer and Genentech.

SOURCE: Avila et al. JOP. 2019 Apr 4. doi:10.1200/JOP.18.00706.

High-cost hospital stays among elderly patients with cancer are associated with major procedures, more comorbid conditions, hematologic cancer, and metastatic cancer, according to a retrospective analysis of more than 570,000 inpatient visits.

Patients involved in the top 10% most expensive cancer-related hospital visits were more likely to have five or more comorbidities, or receive chemotherapy, reported lead author Jaqueline Avila, PhD candidate at the University of Texas Medical Branch in Galveston, and her colleagues.

“A small fraction (approximately 10%) of patients account for more than half of the overall health care costs incurred annually,” the investigators wrote. The report is in the Journal of Oncology Practice.

“[S]imilar to the general population, a small population of patients with cancer (the top 5% to 10% of patients with highest costs) accounts for more than 80% of the total cancer costs,” the investigators wrote. “However, we lack a detailed understanding of the characteristics of these high-cost and high-risk elderly patients with cancer.”

To gain insight, the investigators analyzed 574,367 cancer-related inpatient visits of patients aged 65 years or older, using data from the 2014 National Inpatient Sample. Visits were divided based on cost, with the top 10% most expensive visits in one group (n = 57,437) and the lower 90% of visits in another group (n = 516,930). The investigators then compared these groups based on a variety of patient factor covariates, including race, sex, age, type of cancer, comorbidities, treatments received, and hospital characteristics, such as private or public ownership and location.

The overall median cost of the top 10% of inpatient visits was $38,194 (interquartile range, $31,405-$51,802), compared with $8,257 in the lower-cost group (interquartile range, $5,032-$13,335). This was partly attributed to comorbidities. In the high-cost group, 38.4% of patients had five or more comorbidities, compared with 26.2% in the lower-cost group (P less than .001).

Procedures also factored into cost. The high-cost group had more procedures than did the lower-cost group (mean, 5.48 vs. 2.36; P less than .001), and expensive stays more often entailed major procedures (67.1% vs. 24.3%; P less than .001). Hematologic cancer and metastatic cancer were also more common in the high-cost group than in the lower-cost group, with rates of 23.5% versus 14.6% and 16.5% versus 11.8%, respectively. Among all cancer types, lymphoma, leukemia, and myeloma were the most expensive. The investigators noted that 97.9% of stem-cell or bone marrow transplants were received by patients with hematologic cancer.

Cost did not increase directly with age, as patients aged 65-84 years were more likely to have high-cost inpatient visits than were those who were aged 85 years or older.

The investigators suggested that complications of chronic diseases were likely at the root of this difference, particularly among patients in the 65- to 72-year range. “The difference in costs could also be because caregivers and clinicians may choose to provide only necessary and often less intensive procedures and care to the oldest patients,” the investigators wrote.

A variety of other factors were associated with high-cost visits, although to a lesser degree, including male sex, treatment at a metropolitan teaching hospital, higher median household income, radiation therapy, and large bed size.

The investigators stated that more research is needed to determine relationships between costs and medical necessity, and to develop strategies for reducing costs.

“Although we evaluated the drivers of hospital costs, we could not assess whether additional costs incurred by the high-cost group were medically necessary or could be prevented or whether these excess costs resulted in better outcomes,” the investigators wrote. “Additional research is needed to measure outcomes such as survival and quality of life in this high-cost group and also evaluate whether the excess cost is spent on medically necessary services.

“Future studies should address how implementation of models such as the integrative care model and hospice care may affect the distribution of high-cost and low-cost visits,” the investigators suggested.

Novartis funded the study. Dr. Chavez-MacGregor reported financial relationships with Pfizer and Genentech.

SOURCE: Avila et al. JOP. 2019 Apr 4. doi:10.1200/JOP.18.00706.

High-cost hospital stays among elderly patients with cancer are associated with major procedures, more comorbid conditions, hematologic cancer, and metastatic cancer, according to a retrospective analysis of more than 570,000 inpatient visits.

Patients involved in the top 10% most expensive cancer-related hospital visits were more likely to have five or more comorbidities, or receive chemotherapy, reported lead author Jaqueline Avila, PhD candidate at the University of Texas Medical Branch in Galveston, and her colleagues.

“A small fraction (approximately 10%) of patients account for more than half of the overall health care costs incurred annually,” the investigators wrote. The report is in the Journal of Oncology Practice.

“[S]imilar to the general population, a small population of patients with cancer (the top 5% to 10% of patients with highest costs) accounts for more than 80% of the total cancer costs,” the investigators wrote. “However, we lack a detailed understanding of the characteristics of these high-cost and high-risk elderly patients with cancer.”

To gain insight, the investigators analyzed 574,367 cancer-related inpatient visits of patients aged 65 years or older, using data from the 2014 National Inpatient Sample. Visits were divided based on cost, with the top 10% most expensive visits in one group (n = 57,437) and the lower 90% of visits in another group (n = 516,930). The investigators then compared these groups based on a variety of patient factor covariates, including race, sex, age, type of cancer, comorbidities, treatments received, and hospital characteristics, such as private or public ownership and location.

The overall median cost of the top 10% of inpatient visits was $38,194 (interquartile range, $31,405-$51,802), compared with $8,257 in the lower-cost group (interquartile range, $5,032-$13,335). This was partly attributed to comorbidities. In the high-cost group, 38.4% of patients had five or more comorbidities, compared with 26.2% in the lower-cost group (P less than .001).

Procedures also factored into cost. The high-cost group had more procedures than did the lower-cost group (mean, 5.48 vs. 2.36; P less than .001), and expensive stays more often entailed major procedures (67.1% vs. 24.3%; P less than .001). Hematologic cancer and metastatic cancer were also more common in the high-cost group than in the lower-cost group, with rates of 23.5% versus 14.6% and 16.5% versus 11.8%, respectively. Among all cancer types, lymphoma, leukemia, and myeloma were the most expensive. The investigators noted that 97.9% of stem-cell or bone marrow transplants were received by patients with hematologic cancer.

Cost did not increase directly with age, as patients aged 65-84 years were more likely to have high-cost inpatient visits than were those who were aged 85 years or older.

The investigators suggested that complications of chronic diseases were likely at the root of this difference, particularly among patients in the 65- to 72-year range. “The difference in costs could also be because caregivers and clinicians may choose to provide only necessary and often less intensive procedures and care to the oldest patients,” the investigators wrote.

A variety of other factors were associated with high-cost visits, although to a lesser degree, including male sex, treatment at a metropolitan teaching hospital, higher median household income, radiation therapy, and large bed size.

The investigators stated that more research is needed to determine relationships between costs and medical necessity, and to develop strategies for reducing costs.

“Although we evaluated the drivers of hospital costs, we could not assess whether additional costs incurred by the high-cost group were medically necessary or could be prevented or whether these excess costs resulted in better outcomes,” the investigators wrote. “Additional research is needed to measure outcomes such as survival and quality of life in this high-cost group and also evaluate whether the excess cost is spent on medically necessary services.

“Future studies should address how implementation of models such as the integrative care model and hospice care may affect the distribution of high-cost and low-cost visits,” the investigators suggested.

Novartis funded the study. Dr. Chavez-MacGregor reported financial relationships with Pfizer and Genentech.

SOURCE: Avila et al. JOP. 2019 Apr 4. doi:10.1200/JOP.18.00706.